Abstract:Die massiven wissenschaftlichen Aktivitäten zur Bewältigung der Coronapandemie haben für bestimmte intensivmedizinisch relevante Syndrome neue Blickwinkel und Perspektiven eröffnet. Neben der Sepsis betrifft dies das akute Lungenversagen als schwerste Manifestation der COVID-19-Infektion. In diesem Beitrag soll untersucht werden, ob sich daraus bereits neue Empfehlungen zur Diagnostik und Therapie des ARDS im Allgemeinen ableiten lassen. ARDS is a syndrome that can develop as a result of various underlying diseases. For a long time, the prevailing belief was that the course of the disease was comparable regardless of the underlying disease. However, even before the COVID-19 pandemic, it was suspected that there were different manifestations that could be treated more individually and thus reduce the high mortality rate of ARDS, which has remained unchanged for years. The various findings on the heterogeneity of the course of the disease in COVID-related ARDS appear to confirm these assumptions. It is therefore to be expected that the diagnosis and treatment of non-COVID-related ARDS will also have to be individualised according to such phenotypes in the future. However, as long as the effectiveness of such strategies has not been proven in clinical trials, the current recommendations for ARDS therapy will remain valid for the time being. However, the adjustments already formulated in this context to individual pathophysiological conditions with regard to respiratory mechanics, ventilation-perfusion distribution and possible cardiac dysfunction should be made more meticulously than has usually been the case to date. Die Letalität des ARDS bleibt trotz Beachtung der aktuellen Therapieempfehlungen unverändert. Bereits vor der COVID-19-Pandemie zeichnete sich ab, dass die Differenzierung des ARDS in verschiedene Phänotypen zusätzliche Therapieoptionen zulassen könnte. Insbesondere die Unterscheidung zwischen hyper- und hypoinflammatorischen Verläufen schien in dieser Hinsicht erfolgversprechend. Die im Rahmen der COVID-Pandemie gewonnenen Erkenntnisse zu heterogenen Krankheitsverläufen und entsprechend individualisierten Therapiestrategien lassen sich mit dieser Annahme in Einklang bringen. Es erscheint daher auch beim nicht COVID-bedingten ARDS sinnvoll, Subgruppen mit unterschiedlicher Krankheitsausprägung zu identifizieren. Die Steuerung einer entsprechend individualisierten Therapie mithilfe von Biomarkern ist dabei vielversprechend. Article published online: 08 January 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Drug–Drug Interactions in Patients with Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome and COVID-19: A Literature Review

Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis

Investigational pharmacological agents for the treatment of ARDS

Association between emergency department disposition and mortality in patients with COVID-19 acute respiratory distress syndrome

Risk factors for acute respiratory distress syndrome in sepsis patients: A meta-analysis

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

ARDS-Diagnostik und -Therapie nach der Coronapandemie – alles beim Alten?

Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia

A Retrospective Cohort Analysis of Analgosedation Requirements in COVID-19 Compared to Non-COVID-19 Extracorporeal Membrane Oxygenation Patients

Respiratory Drive, Effort, and Lung-Distending Pressure during Transitioning from Controlled to Spontaneous Assisted Ventilation in Patients with ARDS: A Multicenter Prospective Cohort Study

Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients

Analgesia and sedation in patients with ARDS

Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID‐19): A systematic review

Duration of invasive mechanical ventilation prior to extracorporeal membrane oxygenation is not associated with survival in acute respiratory distress syndrome caused by coronavirus disease 2019

A combination of oxygenation and driving pressure can provide valuable information in predicting the risk of mortality in ARDS patients

Genetic Determinants of the Acute Respiratory Distress Syndrome

Drug-drug-interactions in patients with atrial fibrillation admitted to the emergency department

Modification of Respiratory Drive and Lung Stress by Level of Support Pressure and ECMO Sweep Gas Flow in Patients With Severe COVID-19-Associated Acute Respiratory Distress Syndrome: an Exploratory Retrospective Analysis

Identifying risk factors for acute respiratory distress syndrome in critically ill patients: a retrospective study

Innovations in protective mechanical ventilation for acute respiratory distress syndrome management